MERTK: Tyrosine-protein kinase Mer
Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to several ligands including LGALS3, TUB, TULP1 or GAS6.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on MERTK, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Ningetinib | Phase 2 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Small molecule | InhibitorProto-oncogene tyrosine-protein kinase MER inhibitor | 0 |
- Retinitis pigmentosa0.80
- Inherited retinal dystrophy0.57
- Autosomal recessive retinitis pigmentosa0.52
- Dengue disease0.50
- Hereditary disease0.42
- Retinal disorder0.39
- Leber congenital amaurosis0.39
- Atrial fibrillation0.39
- Posterior column ataxia-retinitis pigmentosa syndrome0.38
- Eye disorder0.37
- Hypertensive disorder0.31
- Atopic eczema0.27
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5331, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt Q12866, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets